PMID- 34974969
OWN - NLM
STAT- MEDLINE
DCOM- 20220621
LR  - 20220705
IS  - 1473-0502 (Print)
IS  - 1473-0502 (Linking)
VI  - 61
IP  - 3
DP  - 2022 Jun
TI  - Variable impact of graft CD3(+) cell content on graft versus host disease in 
      hematopoietic stem cell transplant recipients: Is the role of donor CD3(+) cells 
      overestimated?
PG  - 103349
LID - S1473-0502(21)00357-8 [pii]
LID - 10.1016/j.transci.2021.103349 [doi]
AB  - Graft cellular composition is considered as a significant determinant of 
      transplant outcome. Donor CD3(+) cells were shown to have a significant 
      association with the development of graft vs host disease (GvHD). The aim of this 
      study was to investigate the impact of graft CD3(+) cell content on transplant 
      outcome, particularly in terms of GvHD and relapse. We retrospectively analysed 
      the records of 515 allo-HCT recipients [median age: 37(15-71) years; male/female: 
      323/192]. The optimal threshold of infused CD3(+) cell count for acute GvHD 
      development was estimated to be 197.5 x 10(6)/kg (AUC: 0.572; 95 % CI: 
      0.513-0.631; p = 0.018) and 198.5 x 10(6)/kg (AUC: 0.6; 95 % CI: 0.520-0.679; 
      p = 0.019) for the general population and reduced-intensity conditioning (RIC) 
      subgroup, respectively. Acute GvHD was more frequent in low-CD3(+) group in the 
      whole study population, particularly in RIC transplants. The incidence of 
      cytomegalovirus reactivation was higher in low-CD3(+) group and neutrophil 
      engraftment occured earlier in the same group of patients. Overall survival and 
      non-relapse mortality were comparable between high and low-CD3(+) groups. Age, 
      ECOG performance status, hypogammaglobulinemia, chronic GvHD and post-transplant 
      relapse were found to predict prognosis in multivariate analysis. By focusing 
      mainly on donor T cells, the potential role of host immune cells in the early 
      post-transplant milieu may have been underestimated. Drawing a more detailed 
      profile of graft and host immune cells in the joint microenvironment may 
      elucidate our way to a better understanding of GvHD pathogenesis. By this way a 
      comprehensive pre-transplant risk assessment could be improved to generate more 
      personalized approaches.
CI  - Copyright (c) 2021. Published by Elsevier Ltd.
FAU - Yegin, Zeynep Arzu
AU  - Yegin ZA
AD  - Gazi University Faculty of Medicine, Department of Hematology, Ankara, Turkey. 
      Electronic address: zeyneparzuyegin@gmail.com.
FAU - Bostankolu Degirmenci, Basak
AU  - Bostankolu Degirmenci B
AD  - Gazi University Faculty of Medicine, Department of Hematology, Ankara, Turkey.
FAU - Yazici Sener, Gorkem
AU  - Yazici Sener G
AD  - Gazi University Faculty of Medicine, Department of Internal Medicine, Ankara, 
      Turkey.
FAU - Savas, Emine Merve
AU  - Savas EM
AD  - Gazi University Faculty of Medicine, Department of Hematology, Ankara, Turkey.
FAU - Ozkurt, Zubeyde Nur
AU  - Ozkurt ZN
AD  - Gazi University Faculty of Medicine, Department of Hematology, Ankara, Turkey.
FAU - Koc, Hande Nur
AU  - Koc HN
AD  - Gazi University Faculty of Medicine, Department of Internal Medicine, Ankara, 
      Turkey.
FAU - Ilhan, Cigdem
AU  - Ilhan C
AD  - Gazi University Faculty of Medicine, Department of Hematology, Ankara, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20211229
PL  - England
TA  - Transfus Apher Sci
JT  - Transfusion and apheresis science : official journal of the World Apheresis 
      Association : official journal of the European Society for Haemapheresis
JID - 101095653
MH  - Adult
MH  - Female
MH  - *Graft vs Host Disease
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Humans
MH  - Male
MH  - Recurrence
MH  - Retrospective Studies
MH  - Transplantation Conditioning/adverse effects
MH  - Transplantation, Homologous/adverse effects
OTO - NOTNLM
OT  - Allogeneic stem cell transplantation
OT  - CD3(+) cells
OT  - Cytomegalovirus
OT  - Graft versus host disease
OT  - Reduced intensity conditioning
OT  - T cells
EDAT- 2022/01/04 06:00
MHDA- 2022/06/22 06:00
CRDT- 2022/01/03 05:28
PHST- 2021/10/19 00:00 [received]
PHST- 2021/12/23 00:00 [revised]
PHST- 2021/12/28 00:00 [accepted]
PHST- 2022/01/04 06:00 [pubmed]
PHST- 2022/06/22 06:00 [medline]
PHST- 2022/01/03 05:28 [entrez]
AID - S1473-0502(21)00357-8 [pii]
AID - 10.1016/j.transci.2021.103349 [doi]
PST - ppublish
SO  - Transfus Apher Sci. 2022 Jun;61(3):103349. doi: 10.1016/j.transci.2021.103349. 
      Epub 2021 Dec 29.